从屏障到桥梁:血脑屏障开放治疗高级别胶质瘤的方法、临床疗效与安全性范围综述
该范围综述遵循PRISMA-ScR指南,系统检索37项研究(498例参与者),评估动脉内高渗甘露醇、超声联合微泡、激光间质热疗、脂质体包裹或瑞加德松等BBBD方法治疗成人高级别胶质瘤。超声研究显示脑内药物浓度增加2至5.93倍,癫痫是最常见不良事件,尤其见于动脉内高渗甘露醇(55/146,37.7%)。
要点
- 超声联合微泡有药代动力学证据显示脑内药物浓度增加2至5.93倍。
- 动脉内高渗甘露醇相关癫痫发生率为37.7%(55/146)。
- 生存结局主要来自单臂研究,需前瞻性随机对照试验验证。
核心结论
- BBBD是治疗高级别胶质瘤的有前景策略,有药代动力学证据显示增加脑内药物递送,早期试验报告了探索性生存数据。
研究设计与样本
- 遵循PRISMA-ScR指南的范围综述,系统检索PubMed、Embase、Scopus和Web of Science,纳入37项研究共498例参与者。
主要发现
- 七项超声研究报告药代动力学证据显示脑内药物浓度增加2至5.93倍。
- 影像学反应报告不一,不同模式间不可比较。
- 生存结局主要来自单臂研究,对照臂仅限于非随机或历史对照。
- 癫痫是最常见BBBD相关不良事件,尤其见于动脉内高渗甘露醇(55/146,37.7%)。
关键数值与推荐
- 纳入标准:成人高级别胶质瘤临床研究,测试任何BBBD方法,报告至少一个预设疗效终点(中位总生存期或中位无进展生存期、脑内药物浓度或影像学反应)。
临床怎么用
- BBBD可作为高级别胶质瘤治疗的潜在策略,但需关注动脉内高渗甘露醇相关的癫痫风险。
- 临床 adoption 应基于药代动力学证据和早期探索性数据,并等待前瞻性随机对照试验结果。
局限性
- 生存结局主要来自单臂研究,对照臂限于非随机或历史对照。
- 影像学反应报告不一,不同模式间不可比较。
- 需要纳入现代分子分类的前瞻性随机对照试验来定义未来临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Blood-brain barrier disruption (BBBD) strategies for treating high-grade gliomas (HGGs) have advanced rapidly, yet consensus regarding clinical efficacy remains lacking. A comprehensive review of BBBD methods is needed to consolidate outcomes and guide clinical adoption and research. METHODS: A scoping review following PRISMA-ScR guidelines was performed to identify studies reporting methods and efficacy outcomes of BBBD for HGG. PubMed, Embase, Scopus, and Web of Science were systematically searched. Clinical studies testing any BBBD method in adult HGG were included if they reported at least one predefined efficacy endpoint: median overall or progression-free survival, brain drug concentration, or radiographic response. Neurological adverse events (AEs) attributed to BBBD were recorded. RESULTS: Thirty-seven studies (498 participants) met inclusion criteria and evaluated intra-arterial hyperosmolar mannitol, ultrasound with microbubbles, laser interstitial thermal therapy, liposomal encapsulation, or regadenoson. Seven ultrasound studies reported pharmacokinetic evidence of increased drug delivery, with brain drug concentration increases ranging from 2 to 5.93-fold. Radiographic responses were variably reported and were not comparable across modalities. Survival outcomes were primarily reported in single-arm studies, and use of comparator arms was limited to nonrandomized or historical controls. Seizure was the most common BBBD-associated AE, particularly with intra-arterial hyperosmolar mannitol (55/146, 37.7%). CONCLUSIONS: BBBD represents a promising strategy for HGG treatment, with pharmacokinetic evidence of increased brain drug delivery and exploratory survival data reported in early trials. Although high-grade AEs were uncommon, seizures were prevalent in hyperosmolar mannitol studies. Prospective randomized controlled trials incorporating modern molecular classification are needed to define future clinical applications. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Dufault ME, Akhavan-Sigari A, Pachón-Londoño MJ, et al. From barrier to bridge: a scoping review on the methods, clinical efficacy, and safety of blood-brain barrier disruption in treating high-grade glioma. J Neurooncol. 2026. PMID: 41922786. doi:10.1007/s11060-026-05463-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。